Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma

Trial Profile

Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs TPI 287 (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cortice Bioscience; Cortice Biosciences
  • Most Recent Events

    • 06 Jun 2017 Results of phase I part of this study (n=24) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Results published in a Cortice Bioscience media release.
    • 18 May 2017 According to a Cortice Biosciences media release, final results from the dose-escalation portion of this study will be presented at the 2017 American Society of Clinical Oncology Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top